OBJECTIVE: Systemic lupus erythematosus (SLE) is a complex autoimmune disease characterized by unpredictable flares of disease activity and irreversible damage to multiple organ systems. An earlier study showed that SLE patients carrying an interferon (IFN) gene expression signature in blood have elevated serum levels of IFN-regulated chemokines. These chemokines were associated with more-severe and active disease and showed promise as SLE disease activity biomarkers. This study was designed to validate IFN-regulated chemokines as biomarkers of SLE disease activity in 267 SLE patients followed up longitudinally. METHODS: To validate the potential utility of serum chemokine levels as biomarkers of disease activity, we measured serum levels of CXCL10 (IFNgamma-inducible 10-kd protein), CCL2 (monocyte chemotactic protein 1), and CCL19 (macrophage inflammatory protein 3beta) in an independent cohort of 267 SLE patients followed up longitudinally over 1 year (1,166 total clinic visits). RESULTS: Serum chemokine levels correlated with lupus activity at the current visit (P = 2 x 10(-10)), rising at the time of SLE flare (P = 2 x 10(-3)) and decreasing as disease remitted (P = 1 x 10(-3)); they also performed better than the currently available laboratory tests. Chemokine levels measured at a single baseline visit in patients with a Systemic Lupus Erythematosus Disease Activity Index of < or =4 were predictive of lupus flare over the ensuing year (P = 1 x 10(-4)). CONCLUSION: Monitoring serum chemokine levels in SLE may improve the assessment of current disease activity, the prediction of future disease flares, and the overall clinical decision-making.
OBJECTIVE:Systemic lupus erythematosus (SLE) is a complex autoimmune disease characterized by unpredictable flares of disease activity and irreversible damage to multiple organ systems. An earlier study showed that SLEpatients carrying an interferon (IFN) gene expression signature in blood have elevated serum levels of IFN-regulated chemokines. These chemokines were associated with more-severe and active disease and showed promise as SLE disease activity biomarkers. This study was designed to validate IFN-regulated chemokines as biomarkers of SLE disease activity in 267 SLEpatients followed up longitudinally. METHODS: To validate the potential utility of serum chemokine levels as biomarkers of disease activity, we measured serum levels of CXCL10 (IFNgamma-inducible 10-kd protein), CCL2 (monocyte chemotactic protein 1), and CCL19 (macrophage inflammatory protein 3beta) in an independent cohort of 267 SLEpatients followed up longitudinally over 1 year (1,166 total clinic visits). RESULTS: Serum chemokine levels correlated with lupus activity at the current visit (P = 2 x 10(-10)), rising at the time of SLE flare (P = 2 x 10(-3)) and decreasing as disease remitted (P = 1 x 10(-3)); they also performed better than the currently available laboratory tests. Chemokine levels measured at a single baseline visit in patients with a Systemic Lupus Erythematosus Disease Activity Index of < or =4 were predictive of lupus flare over the ensuing year (P = 1 x 10(-4)). CONCLUSION: Monitoring serum chemokine levels in SLE may improve the assessment of current disease activity, the prediction of future disease flares, and the overall clinical decision-making.
Authors: Kyriakos A Kirou; Christina Lee; Sandhya George; Kyriakos Louca; Ioannis G Papagiannis; Margaret G E Peterson; Ngoc Ly; Robert N Woodward; Kirk E Fry; Anna Yin-Har Lau; James G Prentice; Jay G Wohlgemuth; Mary K Crow Journal: Arthritis Rheum Date: 2004-12
Authors: Uma Sriram; Linda Varghese; Heather L Bennett; Neelakshi R Jog; Debra K Shivers; Yue Ning; Edward M Behrens; Roberto Caricchio; Stefania Gallucci Journal: J Immunol Date: 2012-06-01 Impact factor: 5.422
Authors: Corinna E Weckerle; Beverly S Franek; Jennifer A Kelly; Marissa Kumabe; Rachel A Mikolaitis; Stephanie L Green; Tammy O Utset; Meenakshi Jolly; Judith A James; John B Harley; Timothy B Niewold Journal: Arthritis Rheum Date: 2011-04
Authors: Holden T Maecker; Tamsin M Lindstrom; William H Robinson; Paul J Utz; Matthew Hale; Scott D Boyd; Shai S Shen-Orr; C Garrison Fathman Journal: Nat Rev Rheumatol Date: 2012-05-31 Impact factor: 20.543
Authors: Paul R Dominguez-Gutierrez; Angela Ceribelli; Minoru Satoh; Eric S Sobel; Westley H Reeves; Edward K L Chan Journal: J Clin Immunol Date: 2013-12-01 Impact factor: 8.317
Authors: Brian Scott Ferguson; David A Hoggarth; Dan Maliniak; Kyle Ploense; Ryan J White; Nick Woodward; Kuangwen Hsieh; Andrew J Bonham; Michael Eisenstein; Tod E Kippin; Kevin W Plaxco; Hyongsok Tom Soh Journal: Sci Transl Med Date: 2013-11-27 Impact factor: 17.956
Authors: Payam Fallahi; Richard Katz; Ian Toma; Ranyang Li; Jonathan Reiner; Kiersten VanHouten; Larry Carpio; Lorraine Marshall; Yi Lian; Sujata Bupp; Sidney W Fu; Frederick Rickles; David Leitenberg; Yinglei Lai; Babette B Weksler; Frederik Rebling; Zhaoqing Yang; Timothy A McCaffrey Journal: Gene Date: 2013-02-27 Impact factor: 3.688
Authors: Yen-Yi Ho; Emily C Baechler; Ward Ortmann; Timothy W Behrens; Robert R Graham; Tushar R Bhangale; Wei Pan Journal: Hum Hered Date: 2014-07-30 Impact factor: 0.444